Stevenage, United Kingdom

Claire Ashman

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 5.2

ph-index = 2

Forward Citations = 11(Granted Patents)


Location History:

  • King of Prussia, PA (US) (2010)
  • Stevenage, GB (2014 - 2020)

Company Filing History:


Years Active: 2010-2020

Loading Chart...
Loading Chart...
4 patents (USPTO):

Title: Claire Ashman: Innovator in Protein and Peptide Modifications

Introduction

Claire Ashman is a prominent inventor based in Stevenage, GB. She has made significant contributions to the field of biochemistry, particularly in the development of modified proteins and peptides. With a total of 4 patents to her name, Ashman is recognized for her innovative approaches to addressing complex biological challenges.

Latest Patents

Ashman's latest patents include groundbreaking work on modified proteins and peptides. The present disclosure relates to modified proteins and peptides that have a reduced ability to bind to pre-existing antibodies. Such modified protein and peptide molecules can comprise C-terminal additions, extensions, or tags and/or certain amino acid substitutions. These modified molecules, which include fusions and conjugates, comprise proteins, peptides, antigen-binding molecules, antibodies, or antibody fragments such as single variable domains. The disclosure further relates to uses and formulations of compositions comprising such modified C-terminally extended and/or amino acid substituted molecules, as well as methods of production and expression of these. Another significant invention is directed to antigen-binding constructs comprising one or two epitope binding domains separated by a single chain Fc region of an antibody. Each epitope binding domain is capable of binding to VEGF, and the invention includes pharmaceutical compositions comprising said dimers and their use in treating diseases associated with VEGF signaling, such as diabetic macular edema (DME), wet age-related macular degeneration (Wet AMD), diabetic retinopathy, retinal vein occlusion (RVO), and corneal neovascularization.

Career Highlights

Claire Ashman is currently employed at Glaxo Group Limited, where she continues to push the boundaries of scientific research and innovation. Her work has not only advanced the understanding of protein interactions but has also opened new avenues for therapeutic applications.

Collaborations

Some of her notable coworkers include Alan Peter Lewis and Jonathan Henry Ellis. Their collaborative efforts contribute to the dynamic research environment at Glaxo Group Limited.

Conclusion

Claire Ashman stands out as a leading inventor in the field of modified proteins and peptides. Her innovative patents and contributions to biochemistry highlight her commitment to advancing scientific knowledge and improving therapeutic strategies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…